spacer
home > epc > spring 2017 > transforming software
PUBLICATIONS
European Pharmaceutical Contractor

Transforming Software

With the wide-scale adoption of clinical technologies, focus has slowly shifted from ‘how can we leverage new software and systems in our clinical trials?’ to ‘how can we best implement this software once we’ve chosen it?’ In a highly regulated industry, with patient safety and new treatment advances at stake, the priority has historically been compliance and risk management. Now that these systems are mature and reliable, identifying new ways to make them available in a more efficient and timely manner is important. Utilising iterative design is one way to address these needs.

The Triple Constraint

Anyone who has developed software or managed projects is familiar with the triangle concept – any movement of one factor impacts the equilibrium. For example, increasing the complexity of a clinical supply tool is sure to extend time to implement and development costs. Using an iterative approach helps manage these constraints as well as scope, and maintain quality while reducing time and cost.

Innovation to Date


Quality is of paramount importance with a clinical interactive response technology (IRT) system. When patients are being treated and new drugs developed, quality cannot be compromised. This quality profile must be maintained amid increasingly complex protocol designs, shorter timeline requirements and tighter budgets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Steve Rawbone
spacer
spacer
spacer
Stephane Delegar
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine

VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.
More info >>

White Papers

Case Study: Precision Pen Injector™

SHL Group

The Precision Pen Injector (PPI™) is an injector originally designed to deliver small yet highly precise doses of Restylane® Skinbooster™, a treatment produced by Swedish biomedical firm Q-Med AB (now Galderma) for revitalizing the skin. This innovative device received praises from doctors and clinicians alike for its ease-of-use and compact design at the 2009 IMCAS (International Master Course on Aging Skin), where the product was first officially launched. Furthermore, the PPI™ was recognized with the prestigious red dot design award for product design.
More info >>

 
Industry Events

Symposium on Digitalization and Big Data in Biotech and Pharma

6 June 2018, ETH Zurich, Institute for Chemical and Bioengineering, Vladimir-Prelog-Weg 1

The Symposium on Digitalization and Big Data in Biotech & Pharma will bring together experts and key stakeholders from industry and academia to discuss and current digital innovations and technological trends in the pharmaceutical sector.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement